hydroxychloroquine has been researched along with Smoking Cessation in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Smoking Cessation: Discontinuing the habit of SMOKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-associated death) in patients with cutaneous LE (CLE) or systemic LE (SLE)." | 4.02 | Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. ( Dreyer, L; Egeberg, A; Gislason, G; Haugaard, JH; Kofoed, K; Ottosen, MB, 2021) |
| "Subgroup analyses for the response to antimalarials considering CLE subtypes, type, and dosage of antimalarials could not be performed because of the lack of available data." | 2.52 | Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. ( Amoura, Z; Arnaud, L; Barete, S; Chasset, F; Francès, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kronbichler, A | 1 |
| Effenberger, M | 1 |
| Eisenhut, M | 1 |
| Lee, KH | 1 |
| Shin, JI | 1 |
| Haugaard, JH | 1 |
| Dreyer, L | 1 |
| Ottosen, MB | 1 |
| Gislason, G | 1 |
| Kofoed, K | 1 |
| Egeberg, A | 1 |
| Chasset, F | 1 |
| Francès, C | 1 |
| Barete, S | 1 |
| Amoura, Z | 1 |
| Arnaud, L | 1 |
| Garza-Mayers, AC | 1 |
| McClurkin, M | 1 |
| Smith, GP | 1 |
3 reviews available for hydroxychloroquine and Smoking Cessation
| Article | Year |
|---|---|
Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view.
Topics: Anti-Bacterial Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; | 2020 |
Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
Topics: Antimalarials; Causality; Chloroquine; Cicatrix; Comorbidity; Drug Resistance; Humans; Hydroxychloro | 2015 |
Review of treatment for discoid lupus erythematosus.
Topics: Adrenal Cortex Hormones; Calcineurin Inhibitors; Dapsone; Humans; Hydroxychloroquine; Laser Therapy; | 2016 |
1 other study available for hydroxychloroquine and Smoking Cessation
| Article | Year |
|---|---|
Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Topics: Adult; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Comorbidity; Confounding Factors, Ep | 2021 |